

Letter of Intent Form

Lewy Body Dementia 2026

Instructions

Please complete this form and upload it through the Foundation's grants management system to submit a Letter of Intent (LOI) to the Lewy Body Dementia 2026 Programme.

Before completing the LOI, please review the Programme Guide, including the Programme scope and examples of projects that may be in or out of scope.

Please respond concisely to the four questions below. The **total maximum is 1,400 words**; individual word limits are maxima, not targets. Detailed methods, milestones, budgets and team descriptions are not required at this stage. Up to five key references may be included and will not count towards the word limits.

Application Overview

I. Applicant details

Project title: _____

Principal applicant (one person only): _____

Primary institution: _____

Principal applicant's email address: _____

II. Project type

Please select one:

☐ Biomarker project

☐ Treatment project

☐ Integrated biomarker and treatment project

Select "Integrated biomarker and treatment project" only where the biomarker and treatment components are substantively integrated within the proposed project.

Letter of Intent Form

Lewy Body Dementia 2026

III. Population of interest

Please select one:

- ☐ Dementia with Lewy Bodies (DLB)
- ☐ Parkinson's Disease Dementia (PDD)
- ☐ Both DLB and PDD

IV. Project structure

Is the proposed work embedded within or part of a broader study or clinical trial?

- ☐ Yes
- ☐ No

V. Funding tier

Please select one:

- ☐ **Tier 1:** Up to £350,000 in total for proof-of-concept and early validation studies.
- ☐ **Tier 2:** Up to £750,000 in total for later-stage biomarker validation, clinical translation or implementation, or early-stage clinical treatment studies.

Total funding requested from the Foundation: £_____

Proposed project duration: _____ **months** (*maximum 36 months*)

Project Information

1. Project summary and relevance (*maximum 200 words*)

Provide a concise overview of the proposed project, including its primary objective and how it aligns with the Lewy Body Dementia 2026 Programme.

- **For biomarker projects:** identify the defined candidate biomarker, panel, signature or algorithm, its intended use and its current stage of development, validation, clinical translation or implementation.

Letter of Intent Form

Lewy Body Dementia 2026

- **For treatment projects:** identify the eligible symptom domain being targeted, the proposed intervention and the intended DLB and/or PDD population.
 - **For integrated biomarker and treatment projects:** address both instructions and explain briefly how the components are connected.
-

2. Rationale, unmet need and innovation (*maximum 300 words*)

Describe:

- the unmet need addressed by the proposed project and the specific scientific gap the work aims to fill;
- the preliminary evidence supporting the proposed work;
- what is novel or distinctive about the proposed biomarker, treatment approach or application; and
- why the proposed work is timely.

Preliminary evidence is required for all applications. Up to five key references may be included at the end of the form and will not count towards the word limit.

3. Proposed approach and anticipated evidence (*maximum 600 words*)

Describe the overall approach that will be used to address the project objective. Include only the information needed to understand the study design, population or samples, principal comparisons and anticipated evidence. Detailed methods and a milestone-by-milestone workplan are not required.

- **For biomarker projects:** describe the proposed human validation, clinical translation or implementation approach; the relevant population or cohort; the main comparator; and how biomarker performance or clinical utility will be assessed.
- **For treatment projects:** describe the intervention, target population and study design, and identify the primary outcome measures that will be used to assess clinically meaningful change in the eligible symptom being targeted.

Letter of Intent Form

Lewy Body Dementia 2026

- **For integrated biomarker and treatment projects:** address the relevant elements above and explain how the biomarker and treatment components will be evaluated together.
- **For work embedded within or forming part of a broader study or clinical trial:** identify the component for which Foundation funding is requested, explain how it contributes to the broader study, and confirm that the requested costs do not duplicate costs supported by another funding source.

Briefly identify any essential dependency, such as access to participants, human samples, cohorts or data, needed to deliver the proposed work within the requested project duration.

State the principal result or evidence that would indicate that the proposed study has been successful.

4. Translational path and potential impact (*maximum 300 words*)

Describe:

- how the proposed work could advance biomarker development, validation, clinical translation or implementation, or symptom-focused treatment development for DLB and/or PDD;
- the next stage that would follow if the project is successful; and
- the potential impact on research, clinical development or, ultimately, people living with DLB or PDD.

Where relevant, identify the specific research, development or clinical-trial decision that the results would enable.
